Literature DB >> 8683218

Protective immune responses to the E and NS1 proteins of Murray Valley encephalitis virus in hybrids of flavivirus-resistant mice.

R A Hall1, T N Brand, M Lobigs, M Y Sangster, M J Howard, J S Mackenzie.   

Abstract

The lack of an effective animal model has been a major obstacle in attempts to define the role of humoral and cellular immune responses in protection against flavivirus infection. We have used F1 hybrid mice (BALB/c x C3H/RV) that are heterozygous for the flavivirus resistance allele F1vr and show reduced virus replication in the brain after intracerebral inoculation. F1 hybrid mice challenged by intracerebral inoculation with Murray Valley encephalitis (MVE) virus developed encephalitis 2-3 days later than a genetically susceptible strain (BALB/c) but showed a similar mortality rate. This delay in the onset of disease provided more opportunity for virus clearance by primed immune responses. Using F1 hybrid mice we were able to demonstrate protective immunity induced by structural and non-structural proteins of MVE virus by immunization with pure NS1 protein or recombinant vaccinia viruses that expressed various regions of the MVE genome. These constructs included VV-STR (C-prM-E-NS1-NS2A), VV-delta C (prM-E-Ns1-NS2A) and VV-NS1 (NS1-NS2A). VV-delta C vaccinated mice were completely protected (100% survival)from challenge with 1000 infectious units of MVE virus, while mice inoculated with VV-STR, VV-NS1 or pure NS1 were partially protected (40%, 47% and 85% respectively). Analysis of prechallenge sera and in vivo depletion studies revealed that the solid protection induced by VV-delta C was mediated by neutralizing antibody to the E protein and did not require a CD8+ T cell response. The partial protection provided by VV-STR, VV-NS1 and pure NS1 occurred after induction of antibody to NS1. However, depletion of CD8+ cells prior to virus challenge ablated the protection provided by VV-NS1 indicating some requirement for class I restricted cytotoxic T cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683218     DOI: 10.1099/0022-1317-77-6-1287

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus.

Authors:  Roy A Hall; Debra J Nisbet; Kim B Pham; Alyssa T Pyke; Greg A Smith; Alexander A Khromykh
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-13       Impact factor: 11.205

2.  Vesicular Stomatitis Virus and DNA Vaccines Expressing Zika Virus Nonstructural Protein 1 Induce Substantial but Not Sterilizing Protection against Zika Virus Infection.

Authors:  Anzhong Li; Miaoge Xue; Zayed Attia; Jingyou Yu; Mijia Lu; Chao Shan; Xueya Liang; Thomas Z Gao; Pei-Yong Shi; Mark E Peeples; Prosper N Boyaka; Shan-Lu Liu; Jianrong Li
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

3.  Lack of both Fas ligand and perforin protects from flavivirus-mediated encephalitis in mice.

Authors:  Rosa M Licon Luna; Eva Lee; Arno Müllbacher; Robert V Blanden; Rod Langman; Mario Lobigs
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Evaluation of serum antibody responses against the rotavirus nonstructural protein NSP4 in children after rhesus rotavirus tetravalent vaccination or natural infection.

Authors:  Esmeralda Vizzi; Eva Calviño; Rosabel González; Irene Pérez-Schael; Max Ciarlet; Gagandeep Kang; Mary K Estes; Ferdinando Liprandi; Juan E Ludert
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

5.  Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus.

Authors:  Mario Lobigs; Maximilian Larena; Mohammed Alsharifi; Eva Lee; Megan Pavy
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

6.  Generation of human single-chain variable fragment antibodies specific to dengue virus non-structural protein 1 that interfere with the virus infectious cycle.

Authors:  Ornnuthchar Poungpair; Kunan Bangphoomi; Prapaipit Chaowalit; Nunghathai Sawasdee; Nichapatr Saokaew; Kiattawee Choowongkomon; Wanpen Chaicumpa; Pa-thai Yenchitsomanus
Journal:  MAbs       Date:  2014-01-15       Impact factor: 5.857

Review 7.  Flavivirus NS1 and Its Potential in Vaccine Development.

Authors:  Kassandra L Carpio; Alan D T Barrett
Journal:  Vaccines (Basel)       Date:  2021-06-09

8.  A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein.

Authors:  Anzhong Li; Jingyou Yu; Mijia Lu; Yuanmei Ma; Zayed Attia; Chao Shan; Miaoge Xue; Xueya Liang; Kelsey Craig; Nirajkumar Makadiya; Jennifer J He; Ryan Jennings; Pei-Yong Shi; Mark E Peeples; Shan-Lu Liu; Prosper N Boyaka; Jianrong Li
Journal:  Nat Commun       Date:  2018-08-03       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.